Log In
Print
BCIQ
Print
Print this Print this
 

MGD010

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBispecific antibody against CD32B and CD79b molecule immunoglobulin-associated beta (CD79B; B29) developed using Dual-Affinity Re-Targeting (DART) technology
Molecular Target CD79b molecule immunoglobulin-associated beta (CD79B) (B29)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune diseases
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today